BMY Stock Recent News

Sixteen of the thirty-eight highest-yield, 'safer' S&P 500 dividend stocks are highlighted as ready to buy, with adequate free cash flow supporting payouts. Analyst forecasts suggest top ten S&P 500 dividend 'dogs' could deliver 20.45% to 38.5% net gains by September 2026, with an average gain of 27.35%. Stocks like Amcor, Healthpeak, Conagra, Pfizer, and Verizon offer the best combination of high yield and low price, following the O'Higgins 'Dogs of the Dow' strategy.

Bristol Myers and BioNTech report strong mid-stage lung cancer trial data for pumitamig, showing high response rates and manageable safety.

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Bristol Myers struggles with falling shares and legacy drug headwinds, but growth drugs and new approvals help steady revenues.

In the latest trading session, Bristol Myers Squibb (BMY) closed at $47.23, marking a +1.09% move from the previous day.

BioNTech SE BNTX and Bristol Myers Squibb Co BMY shared interim Phase 2 data on pumitamig (BNT327/BMS986545) plus chemotherapy in patients with untreated extensive-stage small cell lung cancer (ES-SCLC).

Bristol-Myers Squibb Company (NYSE:BMY ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 8:30 AM EDT Company Participants Christopher Boerner - CEO & Chairman Adam Lenkowsky - Executive VP & Chief Commercialization Officer Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst All right. Thanks. I think we're going to get started.

A next-generation cancer immunotherapy by BioNTech and partner Bristol Myers Squibb led to encouraging tumour shrinkage in a mid-stage trial on small cell lung cancer that has started spreading, the German biotech firm said on Monday.

Bristol-Myers Squibb continues to trade below $50, creating a divergence with strong performance from its oncology and cardiovascular franchises. So, sales of its "diamond" in the treatment of non-Hodgkin lymphoma called Breyanzi reached $344 million in Q2 2025, increasing by more than 100% year-on-year. Moreover, Bristol-Myers may expand its label on December 5, 2025, and become the first CAR T-cell therapy in the treatment of relapsed/refractory marginal zone lymphoma.

Bristol-Myers Squibb is a Strong Buy at current levels, with a $54 price target and attractive 5.2% dividend yield. The company's innovative growth portfolio is gaining traction, offsetting legacy declines and positioning BMY for a turnaround. Valuation is compelling: BMY trades at a deep discount to peers, with limited downside and strong profitability metrics.